Ionis director sells 5,000 shares under 10b5-1 plan

Ionis Pharmaceuticals director B. Lynne Parshall reported an open-market sale of common stock.

Accepted by SEC EDGAR 02/13/2026 - 07:40 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ionis Pharmaceuticals director B. Lynne Parshall reported an open-market sale of common stock. On February 11, 2026, Parshall sold 5,000 shares of Ionis common stock at a weighted average price of $82.7177 per share under a pre-established Rule 10b5-1 trading plan adopted on May 6, 2025. After this transaction, Parshall directly beneficially owns 56,344 shares of Ionis common stock.

Insider Trade Summary

Net Seller: 5,000 shares

Net Sell 1 txn

Insider PARSHALL B LYNNE

Role Director

Sold 5,000 shs ($414K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,000	$82.7177	$414K

Holdings After Transaction: Common Stock — 56,344 shares (Direct)

Footnotes (2)

1. F1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.585 to $82.97 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ionis Pharmaceuticals (IONS) report for B. Lynne Parshall?

Ionis director B. Lynne Parshall reported selling 5,000 shares of common stock on February 11, 2026. The sale was an open-market transaction executed under a Rule 10b5-1 trading plan at a weighted average price of $82.7177 per share.

At what price did B. Lynne Parshall sell Ionis (IONS) shares?

The reported weighted average sale price was $82.7177 per share. The shares were sold in multiple transactions within a price range from $82.585 to $82.97, as disclosed in the footnotes to the Form 4 filing.

How many Ionis Pharmaceuticals (IONS) shares does B. Lynne Parshall own after the sale?

Following the reported sale, B. Lynne Parshall beneficially owns 56,344 shares of Ionis common stock. This figure reflects her direct ownership immediately after the 5,000-share open-market transaction on February 11, 2026, as stated in the Form 4.

Was the Ionis (IONS) insider sale by B. Lynne Parshall under a trading plan?

Yes. The 5,000-share sale was made pursuant to a Rule 10b5-1 trading plan. The filing notes the plan was adopted by the reporting person on May 6, 2025, providing for pre-arranged, automatic transactions.

What does the price range disclosure mean in the Ionis (IONS) Form 4?

The filing explains that the reported $82.7177 is a weighted average sale price. Individual trades occurred between $82.585 and $82.97, and detailed trade-price breakdowns are available upon request from Ionis, its security holders, or SEC staff.

What role does B. Lynne Parshall hold at Ionis Pharmaceuticals (IONS)?

B. Lynne Parshall is identified in the filing as a director of Ionis Pharmaceuticals. The Form 4 indicates she is not listed as an officer or 10% owner, and the reported transaction reflects her activity in that director capacity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARSHALL B LYNNE

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		S		5,000(1)	D	$82.7177(2)	56,344	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.585 to $82.97 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: B. Lynne Parshall	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.